Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2006.081695v1, 2007; 10.1373/clinchem.2006.081695
This Article
Right arrow Full Text (PDF)
Right arrow 081695.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.081695v1
53/7/1244    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gray, J. C.
Right arrow Articles by Crisanti, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gray, J. C.
Right arrow Articles by Crisanti, A.

Received on October 11, 2006
Accepted on April 25, 2007

Proteomics and Protein Markers

Profiling the Antibody Immune Response against Blood Stage Malaria Vaccine Candidates

Julian C. Gray 1, Patrick H. Corran 2, Elena Mangia 3, Michael W. Gaunt 4, Qiuxiang Li 1, Kevin K.A. Tetteh 4, Spencer D. Polley 4, David J. Conway 5, Anthony A. Holder 6, Tito Bacarese-Hamilton 1, Eleanor M. Riley 4, Andrea Crisanti 1*

1 Department of Biological Sciences, Imperial College London, London, United Kingdom
2 Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, and Immunology Division, National Institute for Biological Standards and Control, South Mimms, United Kingdom
3 Department of Experimental Medicine, University of Perugia, Perugia, Italy
4 Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom
5 Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom, and MRC Laboratories, Fajara, Banjul, The Gambia
6 National Institute for Medical Research, London, United Kingdom

* To whom correspondence should be addressed. E-mail: acrs{at}imperial.ac.uk.

Background: The complexity and diversity of the antibody immune response to the antigen repertoire of a pathogen has long been appreciated. Although it has been recognized that the detection of antibodies against multiple antigens dramatically improves the clinical sensitivity and specificity of diagnostic assays, the prognostic value of serum reactivity profiles against multiple microbial antigens in protection has not been investigated.

Methods: Using malaria as a model we investigated whether antigen reactivity profiles in serum of children with different levels of clinical immunity to Plasmodium falciparum malaria correlated with protection. We developed a microarray immunoassay of 18 recombinant antigens derived from 4 leading blood-stage vaccine candidates for P. falciparum [merozoite surface protein 1 (MSP1), MSP2, MSP3, and apical membrane antigen (AMA)-1]. Associations between observed reactivity profiles and clinical status were sought using k-means clustering and phylogenetic networks.

Results: The antibody immune response was unexpectedly complex, with different combinations of antigens recognized in different children. Serum reactivity to individual antigens did not correlate with immune status. By contrast, combined recognition of AMA-1 and allelic variants of MSP2 was significantly associated with protection against clinical malaria. This finding was confirmed independently by k-means clustering and phylogenetic networking.

Conclusions: The analysis of reactivity profiles provides a wealth of novel information about the immune response against microbial organisms that would pass unnoticed in analysis of reactivity to antigens individually. Extension of this approach to a large fraction of the proteome may expedite the identification of correlates of protection and vaccine development against microbial diseases.


The following articles in journals at HighWire Press have cited this article:


Home page
 Infect. Immun.Home page
V. Sarda, D. C. Kaslow, and K. C. Williamson
Approaches to Malaria Vaccine Development Using the Retrospectroscope
Infect. Immun., August 1, 2009; 77(8): 3130 - 3140.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
S. K. Pierce and L. H. Miller
World Malaria Day 2009: What Malaria Knows about the Immune System That Immunologists Still Do Not
J. Immunol., May 1, 2009; 182(9): 5171 - 5177.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
F. H. A. Osier, G. Fegan, S. D. Polley, L. Murungi, F. Verra, K. K. A. Tetteh, B. Lowe, T. Mwangi, P. C. Bull, A. W. Thomas, et al.
Breadth and Magnitude of Antibody Responses to Multiple Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Clinical Malaria
Infect. Immun., May 1, 2008; 76(5): 2240 - 2248.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
O. J. Akpogheneta, N. O. Duah, K. K. A. Tetteh, S. Dunyo, D. E. Lanar, M. Pinder, and D. J. Conway
Duration of Naturally Acquired Antibody Responses to Blood-Stage Plasmodium falciparum Is Age Dependent and Antigen Specific
Infect. Immun., April 1, 2008; 76(4): 1748 - 1755.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
F. K. Parekh and T. L. Richie
Characterization of Immune Reactivity Profiles Using Microarray Technology May Expedite Identification of Candidate Antigens for Next Generation Malaria Vaccines
Clin. Chem., July 1, 2007; 53(7): 1183 - 1185.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Association for Clinical Chemistry.